This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Headache Relief for Investors

Click here for an archive of Cramer's "Mad Money" recaps.


"I have a $17 stock for you that, if everything goes right, could easily trade up to $100 per share," Jim Cramer told viewers of his "Mad Money" TV show Friday.

The stock is NMT Medical (NMTI).

It's not a buy-and-hold play, he said, but if you're willing to take some risk it could possibly make you some money fast off of people who suffer from severe migraines.

There's a heart defect called patent foramen ovale (PFO) that affects one in five people and has been connected with an increased likelihood that a person will have migraines, Cramer said. If you close the hole in the heart caused by the defect, it could have a profound impact.

NMT Medical has an implantable, stent-like device called CardioSEAL that could help plug this hole and is already being used to help with strokes, he said. And right now the company is trial testing the device to prove its effectiveness.

If the trial works, I think you'll be hearing about it and paying $100 a share, Cramer said. But, he cautioned, the stock could go below $10 if the trial testing don't work out for the company.

Still, Cramer thinks the potential upside outweighs the downside.

He admitted that he can't say with any authority which way the study will go, but he can say what it will mean if the study shows that the product works.

He came up with the $100-a-share number by looking at the figures NMT Medical offers, including the fact that 3 million people get migraines with aura, the kind associated with the PFO heart defect. These are people who miss work because their migraines are so bad, he added.

Right now at $17 a share, the company has implanted less than 20,000 of these devices worldwide, Cramer said. But if the device proves effective, hundreds of thousands could want it, and there's not a lot of competition on the horizon, he said.

He told a caller that drugmakers with migraine treatments will likely badmouth the product, but that the consumer will decide the winner in this battle and pick the product that actually takes away their pain.

And while he typically does not recommend one-product players, he reminded viewers that buying this stock means going out on a limb and getting into a very speculative play.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs